Ritsner | Polypharmacy in Psychiatry Practice, Volume II | Buch | sack.de

Ritsner Polypharmacy in Psychiatry Practice, Volume II



Use of Polypharmacy in the "Real World"

2013, 321 Seiten, Kartoniert, Previously published in hardcover, Format (B × H): 156 mm x 237 mm, Gewicht: 5153 g
ISBN: 978-94-017-8256-2
Verlag: Springer Netherlands


Ritsner Polypharmacy in Psychiatry Practice, Volume II

Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem. This volume is the first comprehensive, clinically oriented, reference on the multiple medication use to treat psychotic, cognitive, mood and anxiety disorders.

Zielgruppe


Professional/practitioner


Autoren/Hrsg.


Weitere Infos & Material


About the Editor
Preface

Contributors to Volume II

Part 1. Antipsychotic polypharmacy

1. Antipsychotic polypharmacy for schizophrenia: 'Secret sauce' or 'wild abandon'? Peter F. Buckley
2. Antipsychotic polypharmacy in USA. Anand K. Pandurangi, John Vernon

3. Antipsychotic polypharmacy in Czech Republic and in Ukraine. Viktor P. Samokhvalov, Oxana Samokhvalova, Viktoria A. Verbenko, Georgij N. Verbenko

4. Antipsychotic polypharmacy in residential facilities in Italy: the gap between recommendations and real world practice. Lucio Ghio, Werner Natta, Simona Gotelli, Luigi Ferrannini

5. Antipsychotic polypharmacy and associated phenomena in patients with schizophrenia: Rational or irrational? KH Yong, Norman Sartorius, Kang Sim

6. Antipsychotic polypharmacy in schizophrenia. How to counteract this common practice? Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Masaru Mimura
7. Clozapine combinations in treatment-resistant schizophrenia patients. Vladimir Lerner and Chanoch Miodownik

8. Metabolic syndrome and antipsychotic polypharmacy. Fuminari Misawa, Fujii Yasuo, Yasuyuki Okumura, Hiroto Ito

Part 2. Polypharmacy for other psychiatric conditions

9. Evidence based combination therapy for bipolar disorder. Stamatia Magiria, Melina Siamouli, Xenia Gonda, Apostolos Iacovides, Konstantinos N. Fountoulakis

10. Antidepressant combination strategies for major depressive disorder. André F. Carvalho, Danielle S. Macêdo, Thomas N. Hyphantis, Roger S. McIntyre
11. Herbal remedies and nutraceuticals as augmentation or adjunct for mood and anxiety disorders: evidence for benefit and risk. Arun V. Ravindran and Tricia L. da Silva
12. Obsessive-compulsive syndromes in schizophrenia: A case for polypharmacy? Frederike Schirmbeck and Mathias Zink

13. Polypharmacy and potentially inappropriate medication use among elders with dementia. Jan Luzný
14. The role of polypharmacy in bipolar disorder treatment guidelines. Heinz Grunze

Appendix Rena Kurs
1. Annotated bibliography on polypharmacy

2. List of Psychotropic Medications

Contents to Volume I

Contributors to Volume I

Index


WIR VERWENDEN COOKIES

Einige Cookies sind notwendig für den Betrieb der Seite, während andere uns helfen, Ihnen ein optimales Erlebnis unserer Webseite zu ermöglichen.